Merck - 54 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1970 adjusted for splits and dividends. The latest closing stock price for Merck as of March 01, 2024 is 126.96.
  • The all-time high Merck stock closing price was 129.45 on February 23, 2024.
  • The Merck 52-week high stock price is 130.24, which is 2.6% above the current share price.
  • The Merck 52-week low stock price is 99.14, which is 21.9% below the current share price.
  • The average Merck stock price for the last 52 weeks is 110.65.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 122.8931 113.2400 129.4500 113.2400 126.9600 16.46%
2023 106.5287 108.1291 115.9590 99.4567 109.0200 1.00%
2022 85.9565 72.4763 109.0826 69.3083 107.9443 49.38%
2021 71.5562 73.6670 84.5734 65.6689 72.2594 -2.92%
2020 72.2889 81.1795 81.1795 59.0304 74.4314 -7.21%
2019 71.4406 64.9075 80.9149 62.6148 80.2181 22.26%
2018 54.2199 46.8252 67.6411 44.7263 65.6116 40.00%
2017 50.9226 48.6024 54.6359 44.6766 46.8668 -1.47%
2016 45.6737 41.0790 52.0927 38.0341 47.5681 15.05%
2015 43.4626 43.3138 47.7368 37.5696 41.3451 -3.87%
2014 42.6071 36.3662 46.5131 36.3662 43.0108 16.95%
2013 33.4195 29.2873 36.7777 28.9401 36.7777 26.80%
2012 28.6062 26.0466 33.6480 25.3733 29.0039 13.13%
2011 22.6174 23.4060 25.7745 19.7953 25.6385 9.54%
2010 22.8532 23.0473 25.5507 20.0195 23.4060 2.86%
2009 17.9656 18.3096 23.6638 12.6007 22.7546 26.73%
2008 21.3018 32.4321 34.2298 13.7183 17.9553 -45.34%
2007 28.2153 24.1467 34.3542 23.5542 32.8504 37.36%
2006 20.6002 17.2604 25.1342 17.2604 23.9163 42.66%
2005 15.7152 15.6732 17.7238 13.4500 16.7650 4.04%
2004 20.5735 22.7185 23.7214 12.8596 16.1144 -27.76%
2003 24.4000 25.8932 28.4857 19.4392 22.3081 -11.35%
2002 23.6810 25.9003 28.0541 17.1274 25.1642 -1.26%
2001 30.4208 39.4219 39.4219 24.7778 25.4843 -35.79%
2000 30.9935 28.1768 40.1637 22.5817 39.6889 41.78%
1999 30.2547 30.7269 35.5584 25.1875 27.9935 -7.48%
1998 26.2081 21.7319 32.5524 20.7826 30.2551 41.32%
1997 18.8934 15.8390 21.6713 15.8390 21.4087 35.61%
1996 13.3377 12.4720 16.6216 11.1196 15.7874 23.92%
1995 9.4880 7.2626 12.9825 6.9068 12.7398 76.57%
1994 6.1851 6.4431 7.4518 5.2327 7.2153 14.82%
1993 6.3113 7.7849 7.7849 5.1679 6.2840 -18.35%
1992 8.5198 9.6484 9.7928 7.2573 7.6962 -20.29%
1991 6.8876 5.0902 9.6553 4.6779 9.6553 88.88%
1990 4.4347 4.3602 5.1118 3.7462 5.1118 18.95%
1989 3.8601 3.0991 4.4108 3.0991 4.2976 37.47%
1988 2.9233 2.8933 3.1997 2.5612 3.1262 12.05%
1987 2.9591 2.2179 3.8285 2.2179 2.7900 27.96%
1986 1.6829 1.2146 2.2795 1.1915 2.1804 80.83%
1985 0.9664 0.8197 1.2058 0.7955 1.2058 45.75%
1984 0.7800 0.7955 0.8537 0.7019 0.8273 4.00%
1983 0.8004 0.7393 0.9175 0.7217 0.7955 6.81%
1982 0.6766 0.7525 0.7723 0.5655 0.7448 -0.15%
1981 0.7650 0.7569 0.9011 0.6733 0.7459 0.00%
1980 0.6402 0.6227 0.7459 0.5171 0.7459 17.30%
1979 0.5942 0.5974 0.6501 0.5511 0.6359 6.86%
1978 0.5069 0.4719 0.6084 0.4236 0.5951 21.82%
1977 0.4943 0.5897 0.5897 0.4434 0.4885 -18.52%
1976 0.6294 0.6128 0.7074 0.5545 0.5995 -1.64%
1975 0.6555 0.5919 0.7525 0.5171 0.6095 4.33%
1974 0.6325 0.7074 0.7536 0.4313 0.5842 -17.80%
1973 0.7862 0.7965 0.8845 0.6843 0.7107 -9.40%
1972 0.6722 0.5512 0.7877 0.5512 0.7844 43.74%
1971 0.4665 0.4181 0.5754 0.4181 0.5457 25.25%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $321.544B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $743.143B 123.75
Novo Nordisk (NVO) Denmark $557.486B 45.93
Johnson & Johnson (JNJ) United States $390.509B 15.54
AbbVie (ABBV) United States $316.040B 16.10
Novartis AG (NVS) Switzerland $216.326B 14.99
AstraZeneca (AZN) United Kingdom $200.284B 17.75
Pfizer (PFE) United States $150.148B 14.53
Sanofi (SNY) $119.624B 10.77
Innoviva (INVA) United States $0.977B 6.80